IDERA PHARMACEUTICALS INC (IDRA)
US45168K4058 - Common Stock
| MRQ (2022-9-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 26.80M | 32.55M | 33.20M | 40.00M | 71.40M | |||
| Marketable Securities | N/A | 0.00 | 4.50M | 2.80M | N/A | |||
| Receivables | 1.96M | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 1.31M | 1.49M | 3.60M | 3.50M | 1.40M | |||
| Total Current Assets | 30.07M | 34.04M | 41.40M | 46.30M | 72.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 611.00K | 756.00K | 1.00M | 1.20M | 200.00K | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | 9.93M | N/A | N/A | N/A | N/A | |||
| Intangibles | 63.07M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 0.00 | 70.00K | 100.00K | 100.00K | 0.00 | |||
| Total Non-Current Assets | 73.61M | 826.00K | 1.00M | 1.20M | 200.00K | |||
| TOTAL ASSETS | 103.68M | 34.86M | 42.40M | 47.50M | 73.00M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 0.00 | 0.00 | N/A | 0.00 | |||
| Accrued Expenses | 10.94M | 4.30M | 6.30M | 7.60M | 7.90M | |||
| Accounts Payable | 6.76M | 565.00K | 300.00K | 500.00K | 1.10M | |||
| Other Current Liabilities | 1.53M | 0.00 | 400.00K | 46.40M | 0.00 | |||
| Total Current Liabilities | 19.23M | 4.86M | 7.00M | 54.50M | 9.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | 3.90M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 30.61M | 549.00K | 126.50M | 4.10M | 0.00 | |||
| Total Non-Current Liabilities | 34.51M | 549.00K | 126.60M | 4.20M | 0.00 | |||
| TOTAL LIABILITIES | 53.74M | 5.41M | 133.60M | 58.70M | 9.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -748.04M | -735.46M | -833.60M | -720.90M | -664.40M | |||
| Additional Paid In Capital | 768.75M | 764.86M | 742.30M | 709.70M | 728.30M | |||
| Common Shares | 29.23M | 53.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | N/A | N/A | N/A | N/A | N/A | |||
| Shares Outstanding | 59.02M | 52.82M | 38.30M | 29.70M | 27.20M | |||
| Tangible Book Value per Share | -0.89 | 0.56 | -2.38 | -0.38 | 2.35 | |||
| Total Shareholders' Equity | 49.94M | 29.45M | -91.20M | -11.20M | 64.00M | |||
| TOTAL LIABILITIES AND EQUITY | 103.68M | 34.86M | 42.40M | 47.50M | 73.00M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 1.56 | 7.00 | 5.91 | 0.85 | 8.09 | |||
| Return On Assets (ROA) | -17.22% | 278.05% | -265.71% | -178.02% | -82.03% | |||
| Return On Equity (ROE) | -35.75% | 329.14% | N/A | N/A | -93.56% | |||
All data in USD